VTGN Financials

Income Statement
MetricQ1 2027Q4 2026Q3 2026Q2 2026Q1 2026
Revenue
1.5M
+217.4%
465.0K
+53.5%
303.0K
+17.4%
258.0K
+5.7%
244.0K
Cost of Revenue
0
0
0
0
0
Gross Profit
1.5M
+217.4%
465.0K
+53.5%
303.0K
+17.4%
258.0K
+5.7%
244.0K
Operating Expenses
14.8M
-13.7%
17.2M
-13.4%
19.8M
-2.3%
20.3M
+26.6%
16.0M
R&D
10.9M
-16.5%
13.1M
-8.2%
14.2M
-10.6%
15.9M
+36.3%
11.7M
SG&A
3.9M
-4.9%
4.1M
-26.7%
5.6M
+28.0%
4.4M
+0.6%
4.4M
Operating Income
-13348000
+20.2%
-16717000
+14.5%
-19546000
+2.5%
-20053000
-26.9%
-15804000
EBITDA
-13296000
+20.2%
-16665000
+14.5%
-19492000
+2.5%
-20000000
-26.9%
-15764000
Net Income
-13030000
+19.9%
-16274000
+13.9%
-18899000
+2.7%
-19417000
-28.6%
-15095000
EPS (Basic)
$-0.30
+21.1%
$-0.38
+15.6%
$-0.45
+16.7%
$-0.54
-14.9%
$-0.47
EPS (Diluted)
$-0.30
+21.1%
$-0.38
+15.6%
$-0.45
+16.7%
$-0.54
-14.9%
$-0.47
Shares (Diluted)
43.0M
+1.4%
42.4M
+0.3%
42.2M
+18.1%
35.7M
+12.0%
31.9M
Vistagen Therapeutics (VTGN) โ€” Financials